Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
As a multi-purpose healthcare provider, having access to a suture portfolio that is comprehensive is key to meeting you and your patients’ needs. Let Medtronic help you bring out the best in suture — in your hands.
Clinician-trusted for over 20 years, our suture portfolio is here to support your growing needs with competitive pricing and educational resources to help get you started.
V-Loc™ wound closure device is an innovative technology that closes wounds securely without the need to tie knots.1,†
Fast, secure, and effective.2,3 — the V-Loc™ wound closure device may deliver superior wound healing when compared to conventional suture in the initial seven days.4,‡
In addition, the V-Loc™ device:
Your free V‑Loc™ experience kit gives you a hands-on opportunity to feel what it's like to suture with the V‑Loc™ device.
Our absorbable and non-absorbable sutures provide strength retention and absorption profiles to meet your surgical specialty and tissue healing requirements.
Conventional sutures to fit your need:
Absorbable suture:
Non-absorbable suture:
Hear from an expert: Novafil™ suture
Dr. James McLoughlin
Surgical Oncology, University of Tennessee Medical Center
LiquiBand® Exceed™ is a 2-octyl-cyanoacrylate topical skin adhesive with 30 cm of linear coverage per vial,10 it requires up to three times less volume of adhesive to close the same length of wound as Dermabond Advanced.™*11 Its clog-free applicator12 means it can be used for up to 90 minutes of intra-operative time.10,12-14
LiquiBand® Exceed™ XS is a 2-octyl-cyanoacrylate topical skin adhesive with 7 cm of linear coverage13 in a clog-free applicator,12 it can be used for up to 90 minutes of intra-operative time.10,12-14
View the LiquiBand® Exceed™ portfolioThe LiquiBand® XL system provides safe, secure, and effective closure for large and high-tension wounds.15,16,†† With its octyl-based cyanoacrylate formulation, LiquiBand® XL has a number of advantages, including:
SwiftSet™ topical skin adhesive offers a combination of a unique formulation and proprietary application design.
See a demo of SwiftSet™ topical skin adhesive.
Have a representative contact you for more information about ASC therapies and procedures.
Your free V‑Loc™ experience kit gives you a hands-on opportunity to feel what it's like to suture with the V‑Loc™ device.
To order products online, visit:
† Animal data may not correlate with human clinical outcomes.
‡ V-Loc™ device launched in 2009.
§ As compared to conventional sutures.
Ω Bench test data may not be indicative of clinical performance.
†† Tension should be mitigated prior to application according to product IFU. Based on AMS pre-clinical data, may not be indicative of clinical performance.
‡‡ Based on AMS pre-clinical data, may not be indicative of clinical performance.
§§ Based on AMS bench testing data, may not be indicative of clinical performance.
As with all surgical sutures, adverse effects include but not limited to wound dehiscence, failure to provide adequate wound support in sites where expansion, stretching or distention occur. Please refer to instructions for use (IFU) for complete contraindication and risk information.
Zaruby J, Gingras K, Taylor J, Maul D. An in vivo comparison of barbed suture devices and conventional monofilament sutures for cosmetic skin closure: biomechanical wound strength and histology. Aesthet Surg J. 2011;31(2):232-40.
Alessandri F, Remorgida V, Venturini PL, Ferrero S. Unidirectional barbed suture versus continuous suture with intracorporeal knots in laparoscopic myomectomy: a randomized study. J Minim Invasive Gynecol. 2010;17(6):725-729.
Rubin JP, Hunstad JP, Polynice A, Gusenoff JA, et al. A multicenter randomized controlled trial comparing absorbable barbed sutures versus conventional absorbable sutures for dermal closure in open surgical procedures. Aesthet Surg J. 2014;34(2):272-83.
Brown, S. Utilization of a porcine model to demonstrate the efficacy of an absorbable barbed suture for dermal closure, UTSW, June 2009.
Fouda, U. M., Elsetohy, K. A. Elshaer, H. S. Barbed versus conventional suture: A randomized trial for suturing the endometrioma bed after laparoscopic excision of ovarian endometrioma. J. Minim. Invasive Gynecol. 2016;23(6),962-8.
Krishnamoorthy B, Shepherd N, Critchley WR, Nair J, et al. A randomized study comparing traditional monofilament knotted sutures with barbed knotless sutures for donor leg wound closure in coronary artery bypass surgery. Interact Cardiovasc Thorac Surg. 2016;22(2):161-7.
Koide S, Smoll NR, Liew J, Smith K, et al. A randomized 'N-of-1' single blinded clinical trial of barbed dermal sutures versus smooth sutures in elective plastic surgery shows differences in scar appearance two-years post-operatively. J Plast Reconstr Aesthet Surg. 2015;68(7):1003-1009.
Song T, Kim TJ, Kim WY, Lee SH. Comparison of barbed suture versus traditional suture in laparoendoscopic single-site myomectomy. Eur J Obstet Gynecol Reprod Biol. 2015;185:99-102.
Based on internal test report# RE00186732, Medtronic versus Ethicon barbed suture benchtop test evaluation. January 2019.
Based on internal report #001–466, Project Fal wound length claim verification report. January 6, 2015.
Based on internal report #000-558, Wound burst strength testing summary and executive statement. July 2015.
Based on internal report #001–467, Project Fal intraoperative reuse verification report. January 2015.
Based on internal report #003–219, Design verification report: Expressive yield average of adhesive application. September 2018.
Based on internal report #001–309, Design verification report: Project Fal DI 34. September 2014.
Pre-Clinical Safety & Performance Eval Porcine Model 14 Days Section 16.1 and 16.2. May 2021.
Based on AMS report #005-156. LiquiBand® XL Clinical Evaluation Report. Section 9.2 and 10. February 2021.
Based on AMS report #004-956. Microbial Barrier Summary Report LiquiBand® XL™ Zero Time, Section 10. January 2021
Based on AMS report #005-166. Microbial Barrier Summary Report LiquiBand® XL™ 16 Days, Section 9.1 and Section 10.1. May 2021.